Pharmacology of riluzole in acute spinal cord injury. Academic Article uri icon

Overview

MeSH Major

  • Neuroprotective Agents
  • Riluzole
  • Spinal Cord Injuries

abstract

  • This is the first report of clinical pharmacokinetics of riluzole in patients with SCI. The C(max) and AUC(0-12) achieved in SCI patients were lower than those in ALS patients on the same dose basis, due to a higher clearance and larger volume of distribution in SCI patients. The finding in SCI patients of an increase in the clearance and distribution of riluzole between the 3rd and 14th days after SCI, with a lower plasma concentration of riluzole on the 14th day, stresses the importance of monitoring changes in drug metabolism after SCI in interpreting the safety and efficacy of therapeutic drugs that are used in clinical trials in SCI. Clinical trial registration no.: NCT00876889.

publication date

  • September 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 22985379

Additional Document Info

start page

  • 129

end page

  • 40

volume

  • 17

number

  • 1 Suppl